US drug approvals
5 approvals with a product on the US market
- Fosfomycin Tromethamine ANDA217772 · approved 9 Apr 2026
- Pyquvi ANDA219417 · approved 30 Jun 2025
- Zelvysia ANDA218645 · approved 29 Apr 2025
- Motpoly Xr NDA216185 · approved 4 May 2023
- Oxcarbazepine ANDA215332 · approved 30 Nov 2022
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.